The agency granted accelerated approval to Retevmo in RET fusion-positive non-small-cell lung cancer and thyroid cancer and RET-mutated medullary thyroid cancer. The company is mounting a virtual rollout effort as sales staff are grounded due to the Covid-19 pandemic, an exec said.
The trial is the second Phase III study of the RET inhibitor selpercatinib, which Lilly acquired when it bought Loxo Oncology at the beginning of this year for $8 billion.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The next step for the company is to focus on its Percepta Bronchial Genomic Classifier - this was picked up back in 2014 when it brought in $21 million in a deal with Allegro Diagnostics. This test allows doctors to look at 23 genes in cells lining the respiratory tract to better diagnose lung cancer.
Tennessee startup Insight Genetics, a precision medicine company transitioning its diagnostic assays so they work in liquid biopsy, just raised $3 million for its tests that detect breast, thyroid and lung cancers.